<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442699</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2017-0218</org_study_id>
    <nct_id>NCT03442699</nct_id>
  </id_info>
  <brief_title>An Initial Feasibility Study of Brief Cognitive Behavioral Therapy for Suicidal Inpatients</brief_title>
  <official_title>An Initial Feasibility Study of Brief Cognitive Behavioral Therapy for Suicidal Inpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Suicide is a major public health problem. Although inpatient treatment provides immediate
      stabilization and crisis management, the risk of suicide post-discharge is substantial.
      Approximately one third of all suicides by individuals with mental disorders occur in the 90
      days following hospitalization. Cognitive behavioral therapy (CBT) has been shown to reduce
      both suicidal ideation and behavior in outpatients. However, to date, the efficacy of
      inpatient CBT for suicide prevention is not clear. This study aims to 1) develop and
      implement a brief CBT treatment for suicide prevention for inpatients, 2) conduct a brief
      feasibility test and collect initial pilot data on efficacy, and 3) collect preliminary data
      on the effects of CBT on implicit cognitive suicide associations. In Phase 1, the
      investigators will work with an expert in CBT for suicide prevention to modify his treatment
      protocol for use with inpatients, and meet with this expert for a 2-day protocol training. In
      Phase 2, the investigators will conduct an initial feasibility trial with 5-10 inpatients
      recruited from the Institute of Living inpatient units. Participants will be recruited within
      24 hrs of admission or later and will provide written informed consent prior to any study
      procedures. Enrolled participants will undergo a clinical assessment by an independent
      evaluator (IE) that will include diagnostic/symptom assessments, assessment of suicide risk
      using the Columbia-Suicide Rating Scale, and an implicit association test (IAT). Participants
      will receive up to 10 daily sessions of CBT (depending on length of stay), lasting 1 hour,
      following the manualized protocol developed in Phase 1. Participants will then meet with the
      IE again for reassessment after the 10th session or within 24 hr prior to discharge,
      whichever comes first. After discharge, participants will have a telephone interview at 1
      month, 2 month, and 3 month follow-up. The IE will administer the C-SSRS during these calls.
      The proposed study will yield feasibility and initial efficacy data that will be used to
      inform a grant proposal to the American Foundation for Suicide Prevention. That proposal will
      fund a randomized controlled trial of CBT vs. treatment as usual. Concurrently, the
      investigators will develop an in-house program to train other staff in the protocol, and will
      submit a second grant to investigate the efficacy of the training program as well as the
      efficacy of CBT by those clinicians.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale. Suicide is a major public health problem: suicidal ideation affects 14% of the
      adult U.S. population, and as many as 5% have a lifetime history of suicide attempts.1 Among
      individuals with depressive disorders, there is an 11% mortality rate from suicide.2 Although
      inpatient treatment provides immediate stabilization and crisis management, the risk of
      suicide post-discharge is substantial. Approximately one third of all suicides by individuals
      with mental disorders occur in the 90 days following hospitalization.3 A review of nearly 2
      million adult psychiatric inpatients found that the suicide rate in the 90 days after
      discharge for patients diagnosed with depressive disorders was 235.1 per 100,000
      person-years, markedly higher than that in the US general population (14.2 per 100,000
      person-years).4

      Cognitive behavioral therapy (CBT) has been shown to reduce both suicidal ideation and
      behavior.5-8 Though specific protocols vary, typical interventions include problem-solving
      training,9 cognitive restructuring,10 and training in emotion regulation skills.11 To date,
      most of the existing research on CBT has been in outpatient samples, and the efficacy of
      inpatient CBT for suicide prevention is not clear.

      Project Aims. The aims of the proposed project are to:

        1. develop and implement a brief CBT for suicide prevention on the adult inpatient units;

        2. conduct a brief feasibility test and collect initial pilot data on efficacy; and

        3. collect preliminary data on the effects of CBT on implicit cognitive suicide
           associations.

      Method. The investigators selected Rudd et al.'s12 CBT protocol for the proposed project.
      This protocol was tested in a randomized controlled trial (RCT) of outpatients and resulted
      in a significant reduction in suicide attempts over a 24-month follow-up assessment (hazard
      ratio = 0.38); those receiving CBT were 60% less likely to make a suicide attempt than were
      those receiving treatment as usual.13 Of the 6 RCTs that measured suicidal behavior, this was
      the strongest behavioral effect documented.7

      There will be two phases involved in this project, which are described below:

      In Phase 1 of the project, the investigators will work with Dr. Rudd to modify his treatment
      protocol for use in an inpatient setting, and attend a two-day training in the protocol from
      Dr. Rudd.

      In Phase 2 of the project, the investigators will conduct an initial feasibility trial with
      5-10 inpatients.

      Participants. The investigators will recruit 5-10 consecutive adult inpatients (dependent on
      flow within the 6-month treatment window) from the Donnelly units.

      Procedures. It is anticipated that the treatment component of the study will take place over
      a period of six months.

      Participants will be recruited by a member of the research staff on the day following their
      inpatient admission or later (for example in the case of a Saturday admission). Patients who
      meet all of the inclusion criteria and none of the exclusion criteria and agree to
      participate will provide written informed consent prior to any study procedures. Informed
      consent will be documented using the Documentation of Informed Consent Form. For patients who
      are admitted to the hospital involuntarily documentation of competency to provide consent
      will be completed as well. Only those involuntarily committed patients who have been found
      competent to provide informed consent for research will be consented. Patients who decline
      participation will not be approached again. Patients who agree to participation will undergo
      the informed consent process. This process will involve providing the patient with the
      informed consent and HIPAA authorization forms to read. The study staff member obtaining
      consent will highlight the voluntary nature of the research and emphasize that the patient's
      decision whether or not to participate will not impact his &quot;usual care&quot; treatment plan;
      however, patients will also be informed that the information discussed with the study
      clinician is shared with the inpatient treatment team, and thus may be used by them when
      making decisions about discharge planning. Patients will be informed that they may keep the
      forms to review with others if they wish to do so before signing. In addition, all questions
      the patient has about study participation will be answered prior to obtaining written
      consent.

      Enrolled participants will undergo a clinical assessment by an independent evaluator (IE),
      who will administer the DIAMOND, C-SSRS, SIGH-D, and IAT.

      Participants will receive up to 10 daily sessions of CBT (depending on length of stay),
      lasting 1.5 hours for the first session and 1 hour for the remaining sessions, following the
      manualized protocol developed in Phase 1. The CBT protocol is designed to be delivered in two
      phases. In phase I, the therapist conducts a detailed assessment of the patient's most recent
      suicidal episode or suicide attempt, identifies patient-specific factors that contribute to
      and maintain suicidal behaviors, provides a cognitive behavioral conceptualization,
      collaboratively develops a crisis response plan. The crisis response plan is reviewed and
      updated in each session by adding new skills and/or removing skills determined to be
      ineffective, impractical, or too challenging. In phase II, the therapist teaches the patient
      new coping skills inclusion emotion regulation strategies (e.g., relaxation, mindfulness) and
      cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to
      suicidal behavior (e.g., hopelessness, perceived burdensomeness, guilt and shame). During the
      first session of CBT, participants are provided with a small pocket-sized notebook (called a
      &quot;smart book&quot;) in which they are directed to record a &quot;lesson learned&quot; at the conclusion of
      each session. Lessons learned include new skills learned or knowledge gained by participants
      during each session. Participants are encouraged to use the smart book in the future as a
      memory aid for managing emotional distress and solving problems.

      Participants will then meet with the IE again for the C-SSRS, SIGH-D, IAT, and CSQ after the
      10th session or within 24 hrs. prior to discharge, whichever comes first. After discharge,
      participants will have a telephone interview at 1 month, 2 month, and 3 month follow-up. The
      IE will administer the C-SSRS during these calls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive up to 10 daily sessions of CBT (depending on length of stay), for about an hour each day. During this time the therapist will work with participants to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suicidal Ideation Intensity as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity Subscale.</measure>
    <time_frame>Pre-treatment, after treatment which was an average of 16 days, and through follow up, an average of 3 months post-treatment</time_frame>
    <description>The CSSRS intensity subscale measures frequency, duration, controllability, deterrents, and reasons for suicidal ideation. The scale ranges from 2-25 with higher scores indicating more severe suicidal ideation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D)</measure>
    <time_frame>Pre-treatment through post-treatment up to 24 days, 16 days on average</time_frame>
    <description>The SIGH-D is a clinician rated measure of depression symptom severity. Scores range from 0 to 52 with higher total scores indicating more severe depression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Suicide, Attempted</condition>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females

          -  age 18-65 inclusive

          -  fluent in English (speaking, reading, and writing)

          -  having made a suicide attempt within one week preceding admission. Admission will be
             defined as admission to either Hartford Hospital medical floor (in cases where medical
             stabilization is required prior to transfer to IOL) or to IOL (in cases where medical
             stabilization is not required). A suicide attempt will be defined as behavior that is
             self-directed and deliberately results in injury or the potential for injury to
             oneself for which there is evidence, whether explicit or implicit, of intent to die.

        Exclusion Criteria:

          -  age &lt;18 or â‰¥66 years old

          -  history of schizophrenia spectrum disorder

          -  history of mental retardation or organic brain illness

          -  current substance use disorder

          -  active mania or other psychiatric or medical condition that would preclude informed
             consent or participation in the trial, in the investigator's opinion

          -  ECT included on patient's inpatient treatment plan. Patients who are referred for ECT
             after starting the study will be withdrawn from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F Tolin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Living/Hartford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999 Jul;56(7):617-26.</citation>
    <PMID>10401507</PMID>
  </reference>
  <reference>
    <citation>Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med. 1999 Jan-Feb;61(1):6-17. Review.</citation>
    <PMID>10024062</PMID>
  </reference>
  <reference>
    <citation>Huisman A, Kerkhof AJ, Robben PB. Suicides in users of mental health care services: treatment characteristics and hindsight reflections. Suicide Life Threat Behav. 2011 Feb;41(1):41-9. doi: 10.1111/j.1943-278X.2010.00015.x.</citation>
    <PMID>21309823</PMID>
  </reference>
  <reference>
    <citation>Olfson M, Wall M, Wang S, Crystal S, Liu SM, Gerhard T, Blanco C. Short-term Suicide Risk After Psychiatric Hospital Discharge. JAMA Psychiatry. 2016 Nov 1;73(11):1119-1126. doi: 10.1001/jamapsychiatry.2016.2035.</citation>
    <PMID>27654151</PMID>
  </reference>
  <reference>
    <citation>Tarrier N, Taylor K, Gooding P. Cognitive-behavioral interventions to reduce suicide behavior: a systematic review and meta-analysis. Behav Modif. 2008 Jan;32(1):77-108. Review.</citation>
    <PMID>18096973</PMID>
  </reference>
  <reference>
    <citation>Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H. Suicide prevention strategies: a systematic review. JAMA. 2005 Oct 26;294(16):2064-74. Review.</citation>
    <PMID>16249421</PMID>
  </reference>
  <reference>
    <citation>Mewton L, Andrews G. Cognitive behavioral therapy for suicidal behaviors: improving patient outcomes. Psychol Res Behav Manag. 2016 Mar 3;9:21-9. doi: 10.2147/PRBM.S84589. eCollection 2016. Review.</citation>
    <PMID>27042148</PMID>
  </reference>
  <reference>
    <citation>Hepp U, Wittmann L, Schnyder U, Michel K. Psychological and psychosocial interventions after attempted suicide: an overview of treatment studies. Crisis. 2004;25(3):108-17. Review.</citation>
    <PMID>15387237</PMID>
  </reference>
  <reference>
    <citation>Salkovskis PM, Atha C, Storer D. Cognitive-behavioural problem solving in the treatment of patients who repeatedly attempt suicide. A controlled trial. Br J Psychiatry. 1990 Dec;157:871-6.</citation>
    <PMID>2289097</PMID>
  </reference>
  <reference>
    <citation>Brown GK, Ten Have T, Henriques GR, Xie SX, Hollander JE, Beck AT. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA. 2005 Aug 3;294(5):563-70.</citation>
    <PMID>16077050</PMID>
  </reference>
  <reference>
    <citation>Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1991 Dec;48(12):1060-4.</citation>
    <PMID>1845222</PMID>
  </reference>
  <reference>
    <citation>Rudd MD, Joiner TE, Rajab MH. Treating suicidal behavior: An effective, time-limited approach. New York: Guilford Press; 2001.</citation>
  </reference>
  <reference>
    <citation>Rudd MD, Bryan CJ, Wertenberger EG, Peterson AL, Young-McCaughan S, Mintz J, Williams SR, Arne KA, Breitbach J, Delano K, Wilkinson E, Bruce TO. Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. Am J Psychiatry. 2015 May;172(5):441-9. doi: 10.1176/appi.ajp.2014.14070843. Epub 2015 Feb 13.</citation>
    <PMID>25677353</PMID>
  </reference>
  <reference>
    <citation>Tolin DF, Gilliam C, Wootton BM, Bowe W, Bragdon LB, Davis E, Hannan SE, Steinman SA, Worden B, Hallion LS. Psychometric Properties of a Structured Diagnostic Interview for DSM-5 Anxiety, Mood, and Obsessive-Compulsive and Related Disorders. Assessment. 2018 Jan;25(1):3-13. doi: 10.1177/1073191116638410. Epub 2016 Mar 17.</citation>
    <PMID>26988404</PMID>
  </reference>
  <reference>
    <citation>Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.</citation>
    <PMID>22193671</PMID>
  </reference>
  <reference>
    <citation>Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7.</citation>
    <PMID>3395203</PMID>
  </reference>
  <reference>
    <citation>Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J. Behav. Ther. Exp. Psychiatry. 1972;3:257-260</citation>
  </reference>
  <reference>
    <citation>Nock MK, Park JM, Finn CT, Deliberto TL, Dour HJ, Banaji MR. Measuring the suicidal mind: implicit cognition predicts suicidal behavior. Psychol Sci. 2010 Apr;21(4):511-7. doi: 10.1177/0956797610364762. Epub 2010 Mar 9.</citation>
    <PMID>20424092</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <results_first_submitted>October 28, 2019</results_first_submitted>
  <results_first_submitted_qc>December 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2019</results_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>David Tolin</investigator_full_name>
    <investigator_title>Director, Anxiety Disorders Center</investigator_title>
  </responsible_party>
  <keyword>cognitive behavioral therapy</keyword>
  <keyword>suicidal ideology</keyword>
  <keyword>suicidal behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Suicide, Attempted</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03442699/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>8 participants were consented. Two were excluded for comorbid substance use disorder. 6 participants initiated treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>8 participants were consented. 2 were excluded for comorbid substance use disorder. 6 initiated treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Behavioral Therapy</title>
          <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.50" spread="15.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>sex was self-reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Suicidal Ideation Intensity as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity Subscale.</title>
        <description>The CSSRS intensity subscale measures frequency, duration, controllability, deterrents, and reasons for suicidal ideation. The scale ranges from 2-25 with higher scores indicating more severe suicidal ideation.</description>
        <time_frame>Pre-treatment, after treatment which was an average of 16 days, and through follow up, an average of 3 months post-treatment</time_frame>
        <population>On participant was lost to follow-up and did not complete the 3 month follow-up assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Pre Cognitive Behavioral Therapy</title>
            <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
          </group>
          <group group_id="O2">
            <title>Post Cognitive Behavioral Therapy</title>
            <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
          </group>
          <group group_id="O3">
            <title>3 Month Follow-up</title>
            <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Ideation Intensity as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity Subscale.</title>
          <description>The CSSRS intensity subscale measures frequency, duration, controllability, deterrents, and reasons for suicidal ideation. The scale ranges from 2-25 with higher scores indicating more severe suicidal ideation.</description>
          <population>On participant was lost to follow-up and did not complete the 3 month follow-up assessment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="6.51"/>
                    <measurement group_id="O2" value="2.50" spread="6.12"/>
                    <measurement group_id="O3" value="2.60" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D)</title>
        <description>The SIGH-D is a clinician rated measure of depression symptom severity. Scores range from 0 to 52 with higher total scores indicating more severe depression.</description>
        <time_frame>Pre-treatment through post-treatment up to 24 days, 16 days on average</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre Cognitive Behavioral Therapy</title>
            <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
          </group>
          <group group_id="O2">
            <title>Post Cognitive Behavioral Therapy</title>
            <description>Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
Cognitive Behavioral Therapy: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D)</title>
          <description>The SIGH-D is a clinician rated measure of depression symptom severity. Scores range from 0 to 52 with higher total scores indicating more severe depression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="7.97"/>
                    <measurement group_id="O2" value="6.17" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Pre-treatment, after treatment up to 24 days, and through follow up, an average of 3 months post-treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cognitive-Behavioral Therapy</title>
          <description>All participants received cognitive-behavioral therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <description>patient vomited during one of the CBT sessions.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Tolin, Ph.D.</name_or_title>
      <organization>Hartford Hospital/Institute of Living</organization>
      <phone>860-545-7685</phone>
      <email>david.tolin@hhchealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

